Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of TD-6424 against Staphylococcus aureus.

Literature DB >> 14576125

In vitro activity of TD-6424 against Staphylococcus aureus.

John L Pace¹, Kevin Krause, Deborah Johnston, Dmitri Debabov, Terry Wu, Lesley Farrington, Cassie Lane, Deborah L Higgins, Burt Christensen, J Kevin Judice, Koné Kaniga.

Abstract

TD-6424, a rapidly bactericidal agent with multiple mechanisms of action, is more potent in vitro and more rapidly bactericidal than currently available agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. TD-6424 produces a postantibiotic effect with a duration of 4 to 6 h against these organisms. The results suggest potential efficacy against susceptible and resistant strains of S. aureus.

Entities: Chemical Species

Mesh：

Substances：
Anti-Infective Agents

Year: 2003 PMID： 14576125 PMCID： PMC253794 DOI： 10.1128/AAC.47.11.3602-3604.2003

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

3 in total

Review 1. The emergence and evolution of methicillin-resistant Staphylococcus aureus.

Authors: K Hiramatsu; L Cui; M Kuroda; T Ito
Journal: Trends Microbiol Date: 2001-10 Impact factor: 17.079

Review 2. Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance.

Authors: M C Maranan; B Moreira; S Boyle-Vavra; R S Daum
Journal: Infect Dis Clin North Am Date: 1997-12 Impact factor: 5.982

3. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991.

Authors: A L Panlilio; D H Culver; R P Gaynes; S Banerjee; T S Henderson; J S Tolson; W J Martone
Journal: Infect Control Hosp Epidemiol Date: 1992-10 Impact factor: 3.254

3 in total

31 in total

1. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

Authors: Alasdair P MacGowan; Alan R Noel; Sharon Tomaselli; Heather C Elliott; Karen E Bowker
Journal: Antimicrob Agents Chemother Date: 2010-11-15 Impact factor: 5.191

Review 2. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors: Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal: Ther Adv Infect Dis Date: 2017-03-08

3. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.

Authors: J P Shaw; J Seroogy; K Kaniga; D L Higgins; M Kitt; S Barriere
Journal: Antimicrob Agents Chemother Date: 2005-01 Impact factor: 5.191

4. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Authors: Deborah L Higgins; Ray Chang; Dmitri V Debabov; Joey Leung; Terry Wu; Kevin M Krause; Erik Sandvik; Jeffrey M Hubbard; Koné Kaniga; Donald E Schmidt; Qiufeng Gao; Robert T Cass; Dane E Karr; Bret M Benton; Patrick P Humphrey
Journal: Antimicrob Agents Chemother Date: 2005-03 Impact factor: 5.191

5. Tissue penetration of telavancin after intravenous administration in healthy subjects.

Authors: Heather K Sun; Kenneth Duchin; Charles H Nightingale; Jeng-Pyng Shaw; Julie Seroogy; David P Nicolau
Journal: Antimicrob Agents Chemother Date: 2006-02 Impact factor: 5.191

6. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.

Authors: Inga Odenholt; Elisabeth Löwdin; Otto Cars
Journal: Antimicrob Agents Chemother Date: 2007-07-09 Impact factor: 5.191

10. Vancomycin analogs: Seeking improved binding of d-Ala-d-Ala and d-Ala-d-Lac peptides by side-chain and backbone modifications.

Authors: Siegfried S F Leung; Julian Tirado-Rives; William L Jorgensen
Journal: Bioorg Med Chem Date: 2009-07-10 Impact factor: 3.641